Health Canada's Drug Product Database (DPD) lists veterinary drug products approved for dogs. Three widely-marketed canine external (systemic/topical ectoparasiticide) antiparasitic products confirmed via the 2026-07-21 DPD online query (drugClass=Veterinary, vetSpecies=Dogs): (1) Bravecto (fluralaner chewable tablet) — 6 Marketed DINs starting at DIN 02425068 (FLURALANER 112.5 MG) plus 4 Marketed DINs of Bravecto topical solution starting at DIN 02454947 (112.5 MG / 0.4 ML); company INTERVET CANADA CORP; Schedule PRESCRIPTION; Veterinary class. (2) NexGard (afoxolaner chewable) — 4 Marketed DINs starting at DIN 02427435 (AFOXOLANER 11.3 MG), 28.3 MG (DIN 02427443), 68 MG (DIN 02427451), 136 MG (DIN 02427478); company BOEHRINGER INGELHEIM ANIMAL HEALTH CANADA INC.; Schedule PRESCRIPTION. (3) Advantage Multi (imidacloprid + moxidectin topical) — 4 Marketed DINs for dogs starting at DIN 02263556 (IMIDACLOPRID 40 MG / 0.4 ML); company ELANCO CANADA LIMITED; Schedule PRESCRIPTION. The full canine veterinary DPD subset contains 1,077 product rows (HTML table) on 2026-07-21, with status distribution: Cancelled Post Market 447; Marketed 360; Dormant 140; Approved 88; Cancelled Pre Market 29; Cancelled (Unreturned Annual) 13. Across all pet veterinary subsets (Dogs + Cats + "Dog or cat", 1,810 raw rows, 1,312 unique DINs), the topical/systemic ectoparasiticide actives fluralaner (10 Bravecto Marketed DINs for dogs), afoxolaner (4 NexGard Marketed DINs), imidacloprid (4 Advantage Multi Marketed DINs for dogs + 2 for cats), and selamectin (32 product rows incl. Revolution) dominate the Marketed canine external antiparasitic lines.
Source: https://health-products.canada.ca/dpd-bdpp/search-recherche (Health Canada DPD online query, drugClass=Veterinary, vetSpecies=Dogs, status=all), raw HTML retained at pdf-raw/ca-2026/dpd/_raw/dpd_dogs_vet_search_20260721.html.